Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase by Grossi, Valentina & Simone, Cristiano
Hindawi Publishing Corporation
Journal of Oncology
Volume 2012, Article ID 382159, 7 pages
doi:10.1155/2012/382159
Review Article
SpecialAgents HuntingDown WomenSilentKiller:
TheEmergingRole ofthep38α Kinase
Valentina Grossi andCristianoSimone
Laboratory of Signal-dependent Transcription, Department of Translational Pharmacology (DTP), Consorzio Mario NegriSud 66030,
Santa Maria Imbaro, Italy
Correspondence should be addressed to Cristiano Simone, simone@negrisud.it
Received 20 September 2011; Revised 21 December 2011; Accepted 29 December 2011
Academic Editor: Ritu Salani
Copyright © 2012 V. Grossi and C. Simone. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Ovarian cancer is sensitive to chemotherapy with platinum compounds; however, the therapy success rate is signiﬁcantly lowered
by a high incidence of recurrence and by the acquisition of drug resistance. These negative outcomes mainly depend on altered
apoptotic and drug resistance pathways, determining the need for the design of new therapeutic strategies to improve patient
survival. This challenge has become even more critical because it has been recognized that hindering uncontrolled cell growth
is not suﬃcient as the only curative approach. In fact, while current therapies are mostly conceived to impair survival of
highly proliferating cells, several lines of research are now focusing on cancer-speciﬁc features to speciﬁcally target malignant
cells with the aim of avoiding drug resistance and reducing adverse eﬀects. Recently, great interest has been generated by the
identiﬁcation of metabolic reprogramming mechanisms occurring in cancer cells, such as the increase in glycolysis levels. In this
light, pharmacologic manipulation of relevant pathways involved in cancer-speciﬁc metabolism and drug resistance could prove
an eﬀective approach to treat ovarian cancer patients.
1.Introduction
Ovarian cancer has historically been called the “silent killer,”
even if around 80% of patients do actually have symptoms.
Indeed, only 20% of ovarian cancers are currently diagnosed
while still limited to the ovaries, when up to 90% of patients
can be cured using available therapies. Its poor prognosis is
related to late diagnosis, which usually occurs at advanced
stages, and to acquisition of chemoresistance [1]. To date,
more than 30 oncogenes and tumor suppressor genes have
been identiﬁed that are involved in ovarian oncogenesis
inducing modiﬁcations in proliferation, apoptosis, anoikis,
motility, adhesion, and invasion [2].
2. GeneticAlterationsinOvarianCancer
Although ovarian cancer risk is, at least in part, inﬂuenced
by hormonal, environmental, and racial factors, a major role
is played by genetic factors. Indeed, a key advance in the
studyofovariancanceretiologyhasbeentheidentiﬁcationof
mutations in the BRCA genes. BRCA1 and BRCA2 genes act
astumorsuppressorgenesand,whenmutated,areassociated
with the accumulation of chromosomal abnormalities and
thus with a higher risk of developing cancer. Inheritance
of mutations in BRCA genes is associated with a 27% to
44% lifetime risk of ovarian cancer. A higher incidence of
carcinomas of the ovary has also been detected in families
aﬀected by the HNPCC syndrome (hereditary nonpolyposis
colorectal cancer) [3], which is caused by mutations in
DNA mismatch repair genes. HNPCC carriers account for
approximately 1% of ovarian cancer patients, and their
estimated lifetime risk of ovarian cancer is 9% to 12% [4].
Mutations in BRAF, KRAS, and erbB2 oncogenes and in
the tumor suppressor PTEN have been found in a large
subset of ovarian cancers [5, 6]. The inactivation of PTEN
and an activating mutation of KRAS are suﬃcient to in-
duceovarianendometrioidcarcinomainamousemodel[7].
Furthermore, mutations of beta-catenin have been detect-
ed both in ovarian carcinomas and in their precursor le-
sions [8]. Indeed, inactivation of the Wnt/beta-catenin and2 Journal of Oncology
the PI3K/PTEN pathways has been shown to induce the
development of endometrioid carcinoma in an engineered
mouse model [9]. The small G-protein RAB25, which
regulates motility, aggressiveness, apoptosis, and autophagy
and mediates survival in response to stress, has also been
found upregulated in the majority of ovarian cancers [10].
The Aurora-A kinase (Aurora-A) is associated with tu-
mor initiation and progression and is overexpressed in var-
ious malignancies. Inhibition of Aurora-A induces cell cycle
arrest and decreases proliferation of epithelial ovarian cancer
stem cells, which represent the chemoresistant population
andactasasourceofrecurrence[11].Allof these andseveral
other ampliﬁed oncogenes are potential targets for ovarian
cancer therapy.
2.1. Chromatin Remodeling and Ovarian Cancer. Molecular
genetic changes in chromatin remodeling genes have been
identiﬁed as a new mechanism in cancer pathogenesis.
ARID1A (BAF250a), which promotes the formation of SWI/
SNF chromatin remodeling complexes containing BRG1 or
BRM, has emerged as a candidate tumor suppressor gene
based on its frequent mutations in gynecological cancers.
46%–57% of ovarian clear cell carcinomas, 40% of uterine
endometrioidcarcinomas,and30%ofovarianendometrioid
carcinomas display somatic sequence mutations in ARID1A
[12–14]. Guan and colleagues recently reported that restor-
ing wild-type ARID1A expression in ovarian cancer cells
that harbor ARID1A mutations is suﬃc i e n tt os u p p r e s sc e l l
proliferation and tumor growth in mice. Moreover, they
showed that ARID1A/BRG1 complexes directly interact with
p53 and that mutations in the ARID1A and TP53 genes
were mutually exclusive in tumor specimens. The regulation
of p53-related genes by ARID1A raises the possibility that
ARID1Acooperatesatthemolecularlevelwithp53toinhibit
tumor growth. In non-transformed cells, ARID1A and p53
act as a pair of gatekeepers that prevent tumorigenesis by
transcriptional activation of tumor-inhibiting downstream
genes, such as CDKN1A and SMAD3. The authors found
that all tumors with mutated ARID1A contained wild-
type TP53 and tumors with mutated TP53 harbored wild-
type ARID1A. Mutations in either ARID1A or TP53 were
suﬃcient to inactivate the ARID1A/BRG1/p53 complex and
silence transcription of CDKN1A and SMAD3. This recent
study suggests a close collaboration between genetic and
epigenetic alterations in cancer pathogenesis [15].
2.2. Imprinting and Ovarian Cancer. Genomic imprinting
is a molecular mechanism that plays an important role in
development, growth, and cell diﬀerentiation in mammals.
However, only 74 genes have been identiﬁed as imprinted
among the over 30,000 that can be expressed in human cells.
Several of these imprinted genes have been implicated in
human oncogenesis. Indeed, while functional inactivation of
non-imprintedgenesusuallyrequirestwogeneticalterations,
loss of function of imprinted genes may occur following
a single genetic or epigenetic event (including loss of
heterozygosity (LOH), hypermethylation, and altered tran-
scriptional regulation) occurring on the single functional
allele. Moreover, in the case of ovarian oncogenesis, spon-
taneous mutations may occur during the proliferation of
ovarian epithelium to repair ovulatory defects. In this light,
downregulation of the imprinted growth-inhibitory genes
Aplasia Ras homologue member I (ARHI) and paternally
expressed 3 (PEG3) may be particularly important in the
pathogenesis of ovarian cancer [16].
ARHI, also known as DIRAS3, is a maternally imprinted
tumor suppressor gene encoding a 26kDa GTPase with
55%–62% homology to Ras and Rap, which inhibits cancer
cell growth, motility, and invasion. It is expressed by ovarian
epithelial cells and is lost or markedly downregulated in
60%–70% of ovarian cancers [17–19]. Loss of ARHI expres-
sion is associated with tumor progression and poor progno-
sis, while its re-expression in cancer cells inhibits signaling
through the Ras/MAPK pathway, induces p21WAF1/CIP1,
and downregulates cyclin D1 [19]. Besides, Lu et al. [16]
demonstrated that ARHI re-expression causes autophagic
death of ovarian cancer cells in culture and participates
directly in autophagosome formation by upregulating the
ATG4 enzyme that processes the microtubule-associated
proteinLC3ItoLC3II.Autophagyisaprocessof“self-eating”
that involves enzymatic digestion and recycling of cellular
constituents in response to stress. While it can contribute
to cancer cell death in response to chemotherapeutic agents
[20],itsroleinoncogenesisremainsambiguousasitmayalso
permit survival of cancer cells in response to environmental
stress or cytotoxic drugs [21–23]. Indeed, induction of
ARHI in xenografts does not kill ovarian cancer cells but
instead induces tumor dormancy [24], and its subsequent
downregulation rapidly resumes cancer growth.
PEG3 is an imprinted gene encoding a 140kD Kruppel-
type (C2H2) zinc-ﬁnger protein that plays an important
role in the p53/c-myc-mediated apoptotic pathway. It is
signiﬁcantly downregulated in the majority of ovarian can-
cers due to promoter hypermethylation and LOH, and its
re-expression markedly inhibits ovarian cancer growth. Of
note, a high degree of correlation has been found between
ARHI and PEG3 in terms of mRNA levels and promoter
methylation [25].
3. CurrentTherapies and New
Therapeutic Targets
The platinum compounds cisplatin and carboplatin are
the most eﬀective chemotherapy agents currently used in
ovarian cancer. The antitumor activity of cisplatin (cis-di-
amminedichloroplatinum (II)) was discovered by Rosenberg
and colleagues in 1961 [26]. Cisplatin has been the most
active drug used for the treatment of ovarian cancer for the
last 4 decades, and response to cisplatin is considered a prog-
nostic factor for patients with ovarian cancer [27]. A high
percentage of women with ovarian cancer respond to front-
line platinum combination chemotherapy, but in most of
themthediseasewillbecomeresistanttocisplatin,ultimately
leadingtodeath[27].Thus,methodsofpreventingresistance
to cisplatin could prove very useful against ovarian can-
cer.Journal of Oncology 3
The classical therapeutic sequence combines maximal
debulking surgery followed by adjuvant platinum- and pacli-
taxel-based chemotherapy [28, 29]. Unfortunately, 20% of
patients do not respond to chemotherapy and recurrent
disease occur in >50% of those who initially achieve com-
plete remission, with a 5-year overall survival of only 30%–
40% for all stages [30].
New therapeutic approaches based on targeted biologic
agents have generated great interest and are currently being
investigated in several clinical trials focused on treatments
for recurrent ovarian cancer (Figure 1). As is the case for
other cancers, angiogenesis is a key process implicated in
the metastatization of ovarian cancer. Several growth factors,
including vascular endothelial growth factor A (VEGFA),
lysophosphatidic acid (LPA), interleukin 6 (IL6), interleukin
8 (IL8), and ﬁbroblast growth factor 1 (FGF1) and 2 (FGF2)
are involved in this process [31, 32]. To date, agents that
target the VEGF pathway have proven the most eﬀective
against the disease.
VEGFA activity has been inhibited by various mecha-
nisms. Bevacizumab, a VEGFA-speciﬁc antibody, induced an
objective response rate in 16% of patients with recurrent
ovarian cancer and stabilized disease for 5.5 months in 50%
of patients [33], while improved response rates have been
observed in platinum-resistant disease when it was used in
combination with cytotoxic chemotherapy [34]. The VEGF
Trap is based on a diﬀerent approach [35]: it is a fusion
protein that acts as a soluble VEGF receptor and binds
with high aﬃnity to VEGF. Several small molecule inhibitors
have been used in ovarian cancer to target VEGF and
otherpathways.Sorafenib,anoralmultikinaseinhibitorwith
activity against Raf and other receptor kinases (including the
VEGF receptor (VEGFR), the platelet-derived growth factor
receptor (PDGFR), and c-Kit) may have antiangiogenic
eﬀects through inhibition of VEGFR. This inhibitor has
also been used with promising results in combination with
bevacizumab and in combination with chemotherapy, both
in recurrent disease and as initial therapy in newly diagnosed
patients. Sunitinib is an oral agent that inhibits a number
of receptor tyrosine kinases implicated in epithelial ovarian
cancer (EOC) growth and metastasis, including VEGFR and
PDGFR. It has been assessed in phase II studies for the
treatment of advanced or metastatic recurrent EOC [36].
Cediranib (AZD2171) is an oral tyrosine kinase inhibitor
with selective activity against VEGFR1, VEGFR2, VEGFR3,
and c-Kit. Recent clinical trials showed that cediranib has
anticancer activity in recurrent EOC [37]. Pazopanib is an
oral angiogenesis inhibitor targeting VEGFR, PDGFR, and
c-Kit, which is currently being tested in clinical trials on
ovarian cancer.
The epidermal growth factor receptor (EGFR) family is
commonly overexpressed in ovarian cancer and has been
associated with a negative prognosis; however, limited eﬃ-
cacy has been observed with molecules targeted to the EGFR
pathway. Geﬁtinib and erlotinib, which are inhibitors of
EGFR, stabilized disease in 11%–44% of patients with ovar-
ian cancer but produced objective regression in only 4%–
6% of cases [38, 39]. The eﬀect of EGFR inhibitors might be
reduced by activation of the RAS-MAPK signalling pathway,
as happens in colorectal cancers [40]. ErbB2 (also known
as HER2) expression in ovarian cancer is associated with
advancedstage,higherrecurrencefrequency,shortersurvival
time, and lower sensitivity to platinum-based chemotherapy.
Trastuzumab and pertuzumab are humanized antibodies
targeted against HER2, which act through diﬀerent mech-
anisms [41, 42]. In phase II monotherapy clinical studies,
trastuzumab has shown activity in certain ovarian cancers
overexpressing HER2, while pertuzumab is currently under-
going ovarian cancer trials in combination with cytotoxic
agents including gemcitabine [43]a n dc a r b o p l a t i n[ 44].
The estrogen receptor α (ERα) has also been targeted for
the treatment of ovarian cancer. Phase II trials of aromatase
inhibitors (AIs) have shown modest response but rather
better disease stabilization rates, especially when patients are
selected on the basis of ERα expression [45].
Activation of the PI3K pathway, which occurs in approx-
imately 70% of ovarian cancers, is associated with resistance
to cytotoxic chemotherapy. Inhibitors of PI3K and Akt pre-
vent the growth of ovarian cancer xenografts and potentiate
the cytotoxic eﬀects of paclitaxel and cisplatin [46]. Peri-
fosine is an alkylphospholipid compound that inhibits Akt
and is currently being tested in combination with docetaxel.
Development of more speciﬁc Akt inhibitors is currently
underway and PI3K inhibitors are entering phase I-II trials
[47].
Overexpression of IL6 has been detected in the majority
of ovarian cancers. It induces a signaling pathway that ulti-
mately stimulates proliferation, inhibits apoptosis, and pro-
motes angiogenesis. Antibodies against IL6 and inhibitors of
proteinsinvolvedinitspathway,suchasJAK2andSTAT3,are
currently in development for use in ovarian cancer [48].
Upregulation of the LPA receptors LPAR2 and LPAR3
has been described during the malignant transformation of
ovarian surface epithelial cells. An approach targeting this
pathway in ovarian cancer cells through antibodies capable
of neutralizing LPA and through inhibitors of LPA receptors
is currently being studied [49].
Constitutive activation of the NFkB transcription factor
has been observed in the majority of ovarian cancers [50,
51]. Activated NFKB induces upregulation of anti-apoptotic
genes, growth regulatory cytokines (IL6 or growth regulated
α(Gro1)),andangiogenicfactors(IL8)[52].Aclinicaltrialis
currently underway to study the eﬃcacy of liposomal adeno-
viralE1A,whichinterfereswithNFKBsignaling,incombina-
tionwithpaclitaxel in patients withrecurrentovariancancer.
The use of poly(ADP-ribose) polymerase (PARP) inhibi-
tors in ovarian cancer is being evaluated in various preclin-
ical, and clinical studies. By interfering with PARP single-
strand DNA repair activity, this strategy is aimed at increas-
ing the cytotoxicity associated with DNA damage induced
by chemotherapy and takes advantage of the fact that loss
of function of BRCA genes, which are also involved in DNA
strand breaks repair, is a common feature of this type of
cancer[53].Responsetotreatmenthasbeenobservedin46%
of ovarian cancer patients with a BRCA mutation adminis-
teredwiththeoralPARPinhibitorAZD2281(Olaparib)[54].
Moreover, several clinical trials are studying the eﬃcacy of
PARP inhibitors in combination with cytotoxic compounds4 Journal of Oncology
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including monofunctional alkylating agents, topoisomerase-
I poisons and DNA-crosslinking agents [55].
4. p38α andOvarianCancerCellSurvival
Thehighrateofdrugresistanceacquisitionobservedinovar-
ian cancer patients has led to a recent shift in the design of
therapeutic strategies: pathways involved in drug resistance
are being investigated in depth in order to identify new puta-
tive targets, and the potential to manipulate cancer-speciﬁc
features is being evaluated with the aim of speciﬁcally target-
ing tumor cells in order to reduce adverse eﬀects (Figure 1).
As for this second aspect, major attention has been focused
on the metabolic reprogramming occurring in cancer cells,
which display increased levels of glycolysis compared with
their normal counterparts. Indeed, conventional therapies,
such as chemotherapy and radiation, produce heavy adverse
eﬀects because they are mainly designed to aﬀect survival of
highlyproliferatingcellsandthusalsodamagehealthytissues
characterized by a high cellular turnover. In recent years, the
observation made in the 1920s by Nobel Prize winner Otto
Warburg that tumor cells produce 50% of their adenosine
triphosphate through the glycolytic ﬂux versus the 10%
observed in normal cells—the so-called Warburg eﬀect—is
being revalorized and is now considered a promising target
for new therapeutic approaches [56]. This phenomenon is
already successfully exploited for the detection of metastasis
of most epithelial tumors by positron emission tomography
combined with computed tomography (CT; PET/CT) [57,
58]. The Warburg eﬀect seems to be achieved through stable
genetic or epigenetic alterations that promote the constitu-
tive activation of the glycolytic pathway and induce a de-
crease in mitochondrial oxidative phosphorylation, a phe-
nomenon known as aerobic glycolysis.The transcription fac-
tor HIF1α is one of the central players of cancer-speciﬁc
aerobic glycolysis. Indeed, its stabilization leads to overex-
pression of target genes involved in key regulation steps of
glucose transport, glycolysis, lactate production, and lactate/
proton extrusion [59]. Concomitantly, deregulated HIF1α
also induces suppression of mitochondrial metabolic path-
ways, such as oxidative phosphorylation, lipid synthesis, and
β-oxidation [60].
T h er o l eo fH I F 1 α has been well documented in cancers
originating in the ovary. Tumor xenografts obtained from
stable HIF1α-silenced ovarian cancer cells show increased
cell death and necrosis [61], and the expression levels of
HIF1α have been proposed as an independent prognostic
factor in patients with epithelial ovarian tumors [62]. HIF1α
activity is regulated by several pathways, including the
mitogen-activated protein kinase cascade,and p38α hasbeen
demonstrated to be involved in the stabilization of HIF1α
in various normal and cancer cell types [63, 64]. The p38α
pathway regulates proliferation, diﬀerentiation, metabolism,Journal of Oncology 5
and cell death in a cell type-speciﬁc and signal-dependent
manner [65]. Starting from our promising results obtained
on colorectal cancer, showing that p38α blockade promotes
autophagy, cell cycle arrest, and non-apoptotic programmed
cell death both in vitro and in vivo [66–69], we recently
demonstrated that ovarian cancer cells are highly sensitive
to p38α inhibition [70]. Inhibition of p38α activity by the
speciﬁc inhibitor SB202190 impairs the expression of genes
sustaining the altered metabolism of ovarian cancer cell
lines and induces a shift from HIF1α-t oF o x O 3 A - d e p e n d e n t
transcription (Figure 1)[ 70]. SB202190 promotes a time-
dependent reduction of HIF1α protein levels, ultimately
leading to an acute energy need that triggers the activation
of AMPK and the consequent induction of the FoxO3A tran-
scriptional program. In turn, FoxO3A promotes upregula-
tion of crucial mediators of autophagy, cell cycle control, and
cell death. Upon p38α inhibition, autophagy is ﬁrst accom-
panied by G1 arrest, but prolonged inactivation of p38α
leads to autophagic cell death [70]. Autophagy represents a
promising target for the design of new therapeutic strategies
relying on pharmacological manipulation in tumors dis-
playing resistance to apoptosis. Besides, as aerobic glycolysis
representsadiﬀerentiatingfactorbetweennormalandcancer
cells, inhibition of genes involved in cancer cell metabolic
reprogramming may provide both speciﬁcity and eﬃcacy in
countering the energetic demand of transformed cells, thus
hampering growth and inducing energy failure-dependent
death processes. Thus, therapies based on p38α-speciﬁc
inhibitors could represent a valuable tool against cancer.
The rationale to manipulate the p38 pathway in ovarian
cancer is further corroborated by recent ﬁndings indicating
that p38α is a major mediator of drug resistance in response
to chemotherapy with 5-ﬂuorouracil and irinotecan [71, 72].
Moreover, as p38αinhibitorycompoundsarecurrentlybeing
investigated in clinical trials for inﬂammatory diseases and
cancer [73], these ﬁndings might be taken advantage of in
the prospect of clinical translation and support the idea that
p38α could be one of the special agents engaged by clinicians
to hunt down the silent killer.
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